<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02943551</url>
  </required_header>
  <id_info>
    <org_study_id>R01HD084547</org_study_id>
    <nct_id>NCT02943551</nct_id>
  </id_info>
  <brief_title>Dialogue Around Respiratory Illness Treatment</brief_title>
  <acronym>DART</acronym>
  <official_title>Dialogue Around Respiratory Illness Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Portland State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NorthShore University HealthSystem</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>American Academy of Pediatrics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seattle Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Unwarranted use of antibiotics for pediatric acute respiratory tract infections (ARTIs) and
      use of second-line, broad spectrum antibiotics for bacterial ARTIs has contributed to the
      rapid development of resistance in many strains of bacteria. Provider-parent communication
      during pediatric visits for ARTIs strongly influence antibiotic prescribing rates. The
      overall goal of this study is to develop and test a distance learning quality improvement
      (QI) program called Dialogue Around Respiratory Illness Treatment - DART. The DART program
      aims to improve provider communication practices and treatment decisions during pediatric
      ARTI visits, with the ultimate goal being to decrease rates of antibiotic prescribing for
      these illnesses in children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The specific aims of the study are:1) to test the DART program's effectiveness on a) overall
      antibiotic prescribing rates for all pediatric ARTIs and b) first-line antibiotic prescribing
      rates for bacterial ARTIs (acute otitis media, Group A Streptococcal pharyngitis, and
      sinusitis), 2) to test the DART program's effectiveness in changing providers' communication
      practices during ARTI visits, 3) to determine visit-specific satisfaction levels for parents
      of children seen by study providers and assess how satisfaction changes as a function of
      exposure to the DART program, and 4) to assess the cost of implementing the DART program and
      its impact on health care expenditures.

      To accomplish these aims, we propose a quasi-experimental study utilizing a stepped wedge
      design. In collaboration with two practice-based research networks: the electronic Pediatric
      Research in Office Settings (ePROS) network and the NorthShore Pediatric network, we will
      recruit 20 practices to participate. Over a 20 month period, the intervention will be
      sequentially deployed to 4 groups of practices (5 practices/group). Each practice will
      function as part of the control group until they receive the intervention. The DART program's
      effectiveness will be assessed by examining provider antibiotic prescribing rates for ARTIs
      (both overall and first-line), communication practices, and parent satisfaction both pre- and
      post-intervention exposure using survey and electronic health record data. If the DART
      program is effective for both reducing ARTI antibiotic prescribing to levels consistent with
      bacterial prevalence rates and increasing use of first-line antibiotics for bacterial ARTIs,
      we will have an innovative, highly disseminable QI intervention program to further address
      this critical public health problem.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 18, 2016</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in rates of overall antibiotic prescribing for all ARTI visits</measure>
    <time_frame>Two years pre-intervention and, on average, a 15-month period during and post intervention</time_frame>
    <description>This outcome will determine whether rates of prescribing antibiotics during pediatric ARTI visits change as a function of the intervention. A baseline period will be compared to periods both during the intervention and post-intervention. For each time-period, the investigators will assess the number of ARTI visits (denominator) where antibiotics were prescribed (numerator).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in rates of antibiotic prescribing for viral ARTI</measure>
    <time_frame>Two years pre-intervention and, on average, a 15-month period during and post intervention</time_frame>
    <description>This outcome will determine whether rates of prescribing antibiotics during pediatric visits for viral ARTI (bronchitis, non-streptococcal pharyngitis, or viral upper respiratory infection) change as a function of the intervention. A baseline period will be compared to periods both during the intervention and post-intervention. For each time-period, the investigators will assess the number of viral ARTI visits (denominator) where antibiotics were prescribed (numerator).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in rates of antibiotic prescribing for pharyngitis</measure>
    <time_frame>Two years pre-intervention and, on average, a 15-month period during and post intervention</time_frame>
    <description>This outcome will determine whether rates of prescribing antibiotics during pediatric visits for pharyngitis (both non-streptococcal and streptococcal) change as a function of the intervention. A baseline period will be compared to periods both during the intervention and post-intervention. For each time-period, the investigators will assess the number of visits for pharyngitis (denominator) where antibiotics were prescribed (numerator).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in second-line prescribing rates for bacterial ARTIs</measure>
    <time_frame>Two years pre-intervention and, on average, a 15-month period during and post intervention</time_frame>
    <description>These outcomes will determine whether rates of prescribing second-line antibiotics during pediatric visits for streptococcal pharyngitis, sinusitis, and acute otitis media change as a function of the intervention. A baseline period will be compared to periods both during the intervention and post-intervention. For each time-period assessed, the investigators will assess the number of visits for streptococcal pharyngitis, sinusitis, or acute otitis media (denominators) where second-line antibiotics were prescribed (numerators).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Combined Negative and Positive Treatment Recommendations</measure>
    <time_frame>On average 6 months pre-intervention and, on average, 9 months during intervention exposure</time_frame>
    <description>During exposure to the intervention, provider use of combined negative and positive treatment recommendations will increase during visits for ARTI compared to baseline. Investigators will pool parent survey data and calculate rates of positive and negative treatment recommendations for each eligible visit for each period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Contingency plans</measure>
    <time_frame>On average 6 months pre-intervention and, on average, 9 months during intervention exposure</time_frame>
    <description>During exposure to the intervention, provider use of contingency plans will increase during visits for ARTI compared to baseline. Investigators will pool parent survey data and calculate rates of contingency plan use for each eligible visit for each period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parent-Reported Satisfaction Scores</measure>
    <time_frame>On average 6 months pre-intervention and, on average, 9 months during intervention exposure</time_frame>
    <description>Providers exposed to the intervention will have higher parent-reported visit-specific satisfaction scores during exposure to the intervention compared to baseline. To measure satisfaction the investigators will use an adapted version of the 3-item communication composite and the 1-item global visit satisfaction scale from the Consumer Assessment of Healthcare Providers and Systems Clinician and Groups (CG-CAHPSÂ®) Survey. The survey items were adapted so that they are addressed to parents of patients rather than patients themselves. Both the 3-item composite and the 1-item global visit satisfaction scale range from 0-100 with higher scores indicating higher levels of satisfaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost of intervention implementation</measure>
    <time_frame>Two years pre-intervention and, on average, a 15-month period during and post intervention</time_frame>
    <description>The cost of implementing the DART intervention and the cost of any resulting utilization changes will be offset by decreased expenditures on antibiotic prescriptions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in health provider expenditures due to intervention</measure>
    <time_frame>Two years pre-intervention and, on average, a 15-month period during and post intervention</time_frame>
    <description>The cost of implementing the DART intervention and the cost of any resulting utilization changes will be offset by decreased expenditures on antibiotic prescriptions.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2728</enrollment>
  <condition>Respiratory Disease</condition>
  <condition>Acute Respiratory Infection</condition>
  <condition>Respiratory Infection</condition>
  <condition>Upper Respiratory Infection</condition>
  <arm_group>
    <arm_group_label>Providers</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Physicians, pediatric nurse practitioners and physician assistants (referred to as providers from here forward) will be recruited from 20 practices, with a maximum of four providers participating from a single practice, for a maximum of 80 providers.
Providers will receive an online tutorials, interactive group webinars, simulated booster sessions as well as feedback reports.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parents</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The number of parents who participate will depend on the number of providers who agree to participate at each of the 20 practices. The total could range from a minimum of 1800 parents to a maximum of 7200 parents.
Throughout the study, parents at participating practice sites will be offered the opportunity to complete a DART Parent Survey after their child's visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Online Tutorial</intervention_name>
    <description>For each group of practices, during the first month of intervention participation, study staff at Seattle Children's Research Institute will send each participating provider within a group/wedge, via email, a password to access the online tutorial. Participants will be asked to view the 40-minute tutorial at a time that is convenient for them but prior to the first webinar. Investigators will be able to track whether and how often participants access the online tutorial as a measure of engagement in the intervention. PROS will follow up, via email or phone, with providers who have not completed the tutorial within a three week timeframe.</description>
    <arm_group_label>Providers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Webinars</intervention_name>
    <description>The first webinar, focused on making appropriate antibiotic choices for bacterial ARTIs, will be held at the beginning of month 2 of intervention participation, and the second webinar, focused on recommended communication practices during visits for ARTIs, will be held at the beginning of month 3 of intervention participation. Due to webinar faculty time constraints, we will establish dates/times for the webinar prior to recruitment. Providers will be given information on webinar dates in both the randomization email, as well as include the dates in the study box letter.
The webinars will be recorded to facilitate attendance for those who are unable to make the scheduled date/time. Included in the recording will be the presentation and any questions and answers from participants.</description>
    <arm_group_label>Providers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Booster Sessions</intervention_name>
    <description>An online link to the first booster video vignette will be sent to practice participants via email at the beginning of month 5 of intervention participation for each group/wedge. The link will lead to a website in which the provider will need to create a user name and password to access the booster videos. Two additional booster vignettes will be made available for viewing at the beginning of months 7 and 9 of intervention participation.
For each of the three booster sessions, up to three reminders to complete viewing the video vignette will be sent over a 2-week period. The study team will be able to monitor whether participants access and complete the questions at the end of each vignette.</description>
    <arm_group_label>Providers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Feedback Reports</intervention_name>
    <description>During the intervention phase, providers will also receive 6 audit and feedback reports given by parents.
The first report will have two parts:
The first part will focus on the provider's overall antibiotic prescribing rates for all ARTIs (viral and bacterial) and rates of using second-line antibiotics for bacterial ARTIs.
The second part will report the rates at which the provider uses the targeted communication practices as well as their average satisfaction scores.</description>
    <arm_group_label>Providers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Parent Survey</intervention_name>
    <description>Throughout the study, parents at participating practice sites will be offered the opportunity to complete a DART Parent Survey after their child's visit.</description>
    <arm_group_label>Parents</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Visits to enrolled providers by children aged 6 months to 10 years with an International
        Classification of Diseases-10 (ICD-10) diagnosis code for AOM, bronchitis, pharyngitis,
        sinusitis, or upper respiratory infection (URI) will be included in the study. Only
        systemic (oral) antibiotic prescriptions on the same date as the study visit will be
        included in prescribing measures for each ARTI.

        Exclusion Criteria:

        ARTI visits will be excluded from measures of prescribing if there are any competing
        non-ARTI bacterial diagnoses (e.g. urinary tract infection) or any antibiotic prescriptions
        during the 30-days prior to the index visit. Visits by children with allergies to
        penicillin or cephalosporin antibiotics will be excluded from measures of second-line
        prescribing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rita Mangione-Smith, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seattle Children's</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Paragould Pediatrics</name>
      <address>
        <city>Paragould</city>
        <state>Arkansas</state>
        <zip>72450</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eureka Pediatrics</name>
      <address>
        <city>Eureka</city>
        <state>California</state>
        <zip>95503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Partners of the Southwest</name>
      <address>
        <city>Durango</city>
        <state>Colorado</state>
        <zip>81301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Medicine of Wallingford</name>
      <address>
        <city>Wallingford</city>
        <state>Connecticut</state>
        <zip>06492</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advance Preventive Care</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A to Z Pediatric &amp; Youth Healthcare</name>
      <address>
        <city>Addison</city>
        <state>Illinois</state>
        <zip>60101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>All Star Pediatrics</name>
      <address>
        <city>Countryside</city>
        <state>Illinois</state>
        <zip>60525</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deerfield</name>
      <address>
        <city>Deerfield</city>
        <state>Illinois</state>
        <zip>60015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evanston (Central)</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evanston (Davis)</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenview</name>
      <address>
        <city>Glenview</city>
        <state>Illinois</state>
        <zip>60026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gurnee</name>
      <address>
        <city>Gurnee</city>
        <state>Illinois</state>
        <zip>60031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lincolnwood</name>
      <address>
        <city>Lincolnwood</city>
        <state>Illinois</state>
        <zip>60712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Old Orchard</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60077</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vernon Hills</name>
      <address>
        <city>Vernon Hills</city>
        <state>Illinois</state>
        <zip>60061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Plaza Del Lago</name>
      <address>
        <city>Wilmette</city>
        <state>Illinois</state>
        <zip>60091</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East End</name>
      <address>
        <city>East Hampton</city>
        <state>New York</state>
        <zip>11968</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hampton Pediatrics</name>
      <address>
        <city>Southampton</city>
        <state>New York</state>
        <zip>11968</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Plateau Pediatrics</name>
      <address>
        <city>Crossville</city>
        <state>Tennessee</state>
        <zip>38555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornerstone Pediatrics</name>
      <address>
        <city>Seguin</city>
        <state>Texas</state>
        <zip>78155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>August 23, 2016</study_first_submitted>
  <study_first_submitted_qc>October 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2016</study_first_posted>
  <last_update_submitted>July 12, 2019</last_update_submitted>
  <last_update_submitted_qc>July 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seattle Children's Hospital</investigator_affiliation>
    <investigator_full_name>Rita Mangione-Smith</investigator_full_name>
    <investigator_title>Primary Investigator</investigator_title>
  </responsible_party>
  <keyword>Pediatrics</keyword>
  <keyword>Respiratory disease</keyword>
  <keyword>antibiotic use</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>If requested and criteria for receipt are met, data will be shared with investigators outside the DART project team when all planned data collection and analyses are completed. The data shared will be limited to visit-based prescribing rates, patient characteristics, and dummy variables for clinic site (de-identified). No protected health information for study participants will be shared. Data will be provided as a CSV file with a data dictionary defining all variables included in the file. Additional analytic tools will not be provided. Data will be transferred using a secure file transfer protocol.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>The data will be provided after all analyses are completed for a period of 5 years.</ipd_time_frame>
    <ipd_access_criteria>A data use agreement will be required between Seattle Children's Research Institute and any entity requesting access to the data. Those requesting access to the data will be required to provide a detailed plan for their use of the data. This agreement will also require that the requesting investigator/entity obtain permission to publish results based on these data from Seattle Children's Research Institute and the Principal Investigator prior to submission for any such publication.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

